1[1]Mattila K,Haavisto M,Rajala S,et al.Blood pressure and five year survival in the very old[J].Br Med J,1988,296(6626):887-889.
2[2]Gueyffier F,Bulpitt C,Boissel JP,et al.Antihyperten-sive drugs in very old people:a subgroup meta-analysis of randomised controlled trials[J].Lancet,1999,353(9155):793-796.
3[3]Chobanian AV,Bakris GL,Black HR,et al.The Se-venth Report of the Joint National Committee on Preven-tion,Detection,Evaluation,and Treatment of High Blood Pressure:the JNC 7 report[J].JAMA,2003,289(19):2560-2572.
4[4]Mancia G,De Backer G,Dominiczak A,et al.2007 Guide-lines for the Management of Arterial Hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J].J Hyper-tens,2007,25(6):1105-1187.
5[5]Beckett NS,Peters R,Fletcher AE,et al.Treatment of hypertension in patients 80 years of age or older[J].N Engl J Med,2008,358(18):1887-1898.
6[6]Kostis JB.Treating hypertension in the very old[J].N Engl J Med,2008,358(18):1958-1960.
7[7]Jamerson KA.The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events:Avoiding Cardiovascular events through Combination therapy in Patients Living with Sys-tolic Hypertension (ACCOMPLISH)[J].J Clin Hyper-tens,2003,5(4 Suppl 3):29-35.
8[8]Weder AB.The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hy-pertension (ACCOMPLISH) trial:a comparison of first-line combination therapies[J].Expert Opin Pharmaeo-ther,2005,6(2):275-281.
9[9]Yusuf S,Sleight P,Pogue J,et al.Effects of an angioten-sin-converting-enzyme inhibitor,ramipril,on cardiovascu-lar events in high-risk patients.The Heart Outcomes Pre-vention Evaluation Study Investigators[J].N Engl J Med,2000,342(3):145-153.
10[10]ONTARGET Investigators,Yusuf S,Teo KK.Telmisar-tan,ramipril,or both in patients at high risk for vascular events[J].N Engl J Med,2008,358(15):1547-1559.
